DOI: https://doi.org/10.21203/rs.3.rs-2045688/v1
Uveal melanoma is the most common primary intraocular tumor in adults. In Sweden, 60 to 100 patients are diagnosed with the disease each year. Almost half of the patients develop metastases, with a median survival time of 1 year once metastases are detected. The primary ocular tumor is typically treated with either enucleation or brachytherapy, and no adjuvant treatment is added. Melatonin is an indolamine hormone that has improved survival in previous trials with patients diagnosed with various cancers, including advanced cutaneous melanoma. Side effects have been mild. We aim to investigate if adjuvant treatment with melatonin for 5 years following diagnosis of non-metastasized uveal melanoma can decrease the occurrence of metastases.
An open-label, prospective, 5-year randomized clinical trial (RCT) will be conducted at St. Erik Eye Hospital. Patients (n = 100) diagnosed with non-metastatic uveal melanoma will be included in this trial and randomized to either treatment with adjuvant melatonin 20 mg (4 tablets of 5 mg) at 10 pm for five years, or to standard follow-up (control group). The primary outcome measurement is the number of patients that have developed metastases 5 years after randomization. The secondary outcomes are overall survival, risk of developing other cancers, overall survival after detection of metastases, and differences in the occurrence of adverse events (AE) and serious adverse events (SAE) between the groups.
Melatonin has been found to positively impact our immune system, inhibit angiogenesis, stimulate apoptosis in malignant cells, and act as a potent antioxidant. Previous clinical trials have used similar doses of melatonin with positive results, particularly in advanced stages of cancer. Previous animal and human studies have found the toxicity of the hormone to be low. Considering the potential benefits and limited risks of melatonin, as well as its global availability, it may be a suitable candidate for an adjuvant treatment in patients with uveal melanoma.
Our trial protocol has been approved and registered by the Swedish Medical Products Agency on June 22, 2022 (EudraCT 2022-500307-49-00). Our trial registration number is NCT05502900 and the date of registration is August 16, 2022.
In this trial, 100 subjects with non-metastatic uveal melanoma will be randomized to either treatment with melatonin 20 mg at 10 pm for 5 years or to a control group. The main objective is to investigate whether treatment with melatonin can reduce the risk of developing metastases after 3 and 5 years. Only subjects at high risk for metastasis development will be included in the trial. As uveal melanoma has a relatively low incidence rate compared to other cancers, the recruitment period is estimated to take 3 to 4 years.
EU-examination number |
2022-500307-49-00 |
Title |
Adjuvant Melatonin for Uveal Melanoma: A Randomized Open Phase III Study |
Trial code |
AMUM |
Trial registration |
NCT05502900 |
Protocol version |
2.0 |
Funding |
St. Erik Eye Hospital The Swedish Society of Medicine (SLS-971390) The Royal Swedish Academy of Sciences (ME2019-0036) The Swedish Cancer Society (20 0798 Fk) Region Stockholm (RS-2019-1138) The Swedish Eye Foundation (2022-05-02) Karolinska Institutet (FS-2021-0010) |
Authors details |
R Kal Omar1, A Hagström1, G Stålhammar2,3.
1Department of Medicine, Karolinska Institutet, D1:04, 17176 Stockholm, Sweden. 2Department of Clinical Neuroscience, Division of Eye and Vision, St: Erik Eye Hospital, Karolinska Institutet, Stockholm, Sweden. 3St. Erik Eye Hospital, Stockholm, Sweden. |
Trial sponsor |
St. Erik Eye Hospital |
Trial Period |
Q2 2022-Q1 2032 |
About 50% of patients diagnosed with uveal melanoma develop metastases, primarily in the liver.1 This risk is consistent regardless of which method is chosen to treat the primary tumor.2 The most common forms of treatment include enucleation (surgical removal of the tumor containing eye), proton beam irradiation, and plaque brachytherapy – a form of local radiation treatment. Due to very early seeding of micrometastases, the treatment choice typically does not affect the risk of dying from metastatic disease. Micrometastases are clusters of cancerous cells too small to be detected in standard radiological examinations, which migrate from the primary tumor to other organs, such as the liver, where they can remain latent for many years before growing into radiologically detectable tumors, or macrometastases.3 By the time these metastases are detected, the median survival time is one to two years.4,5 This project’s objective is to investigate if adjuvant treatment with melatonin tablets, following diagnosis of the primary tumor, decreases the risk of developing macrometastases of uveal melanoma.
Previous randomized, placebo-controlled studies investigating various types of solid cancers including cutaneous melanoma have found that melatonin can improve 1-year survival significantly.6 A similar impact has been seen in a smaller study, where partial responses or stable disease progression was found in 12 of 40 patients (30%) with advanced cutaneous malignant melanoma taking melatonin after an average follow up of 5 weeks.7 In a third study, adjuvant treatment with melatonin following surgical resection of lymph node metastasized cutaneous malignant melanoma resulted in significantly fewer patients with progression after an average of 31 months compared to the placebo group.8 No melatonin-related toxicity was detected in the treatment groups. In a recently published study on patients with non-small cell lung cancer, a significantly improved progression-free survival was seen in a subgroup of patients with advanced stage disease, however, in another, similar study no such impact was seen after a year of treatment with melatonin.9,10 The overarching factor responsible for melatonin's impact on cancer is believed to be related to its oncostatic properties, including inhibition of tumor cell proliferation, remodeling of the cytoskeleton, antioxidative effects, and stimulation of the immune system.11–13
We have recently described the rationale for adjuvant treatment with melatonin for uveal melanoma in a review of the literature.14 Studies from 1997 and 1998 showed that melatonin can inhibit the growth of uveal melanoma cells with 41 to 50 in a concentration of 0.1 to 10 nM, compared to non-treated cells.15,16 Melatonin’s precursors tryptophan and serotonin have not shown a similar effect.16 Moreover, uveal melanoma appear to express transmembrane receptors for melatonin. In a study performed by Roberts et al., melatonin and its membrane receptor agonists (MT1 and MT2) were found to inhibit the growth of uveal melanoma cells at low concentrations without impacting non-cancerous melanocytes.17
In animal studies, the effects of melatonin on uveal melanoma have varied. In a study performed on mice, the cell-line B16-F10 was injected in the tail vein of melatonin knockout mice which were then treated with melatonin 20 mg/kg. After 15 days, there were no significant differences in the number and size of lung metastases compared to controls.18 Another study performed on a human melanoma xenograft mouse model which were injected with DX3 melanoma cells while receiving injections of melatonin or melatonin analogues UCM 1033 and UCM 1037. When measuring tumor size both four weeks after treatment and after euthanization, the injections of UCM 1033 and UCM 1037 were found to inhibit tumor growth by 40 and 90 respectively, while melatonin provided no significant tumor growth suppression.19 Another study found that mice which received 5µg/g melatonin in their drinking water daily at the time of melanoma inoculation, had a lower size and weight of their melanoma compared to control groups 40 days after administration.20 In a similar study, athymic mice were injected with melanoma cells and received either 5 µg/g body weight of melatonin in their drinking water together with 0.5% ethanol, 0.5% ethanol alone, or neither melatonin nor ethanol. After 40 days, the mice treated with melatonin had tumors lower in both size and weight.20
A meta-analysis published in 2005 suggested that melatonin may have similar therapeutic effects in humans as well. Results found that melatonin treatment in patients with solid tumors was associated with a 44% reduction in the risk of death at one year.6 A clinical trial published in 1991 investigated the effects of melatonin treatment in 40 patients with advanced malignant melanoma, of which, 10 had uveal melanoma.7 Participants were given oral melatonin in doses ranging from 5 to 700 mg/m2 four times a day. After a median follow-up time of 5 weeks, twelve patients showed a response or stable progression of disease. The response appeared to depend, however, on the dose, type of melanoma and metastasis location with a dose of 75 mg/m2 having best effect with minimal side effects, primarily fatigue.7 Another clinical trial including five patients with metastatic melanoma studied the effect of adjuvant treatment with 50 mg melatonin taken orally. While four of the five patients had no response to the therapy, one patient continued taking melatonin for over 8 months and had almost total cancer regression.21 To date, there have been no earlier studies of the long-term effects of melatonin on human patients with uveal melanoma.
The study is an open randomized intervention study without a placebo control. 100 patients will be randomized to either treatment with melatonin 20 mg at 10 pm, or before bedtime, (melatonin group) or to standard follow-up (control group) for a period of 5 years. Aside from treatment with melatonin in the melatonin group, all participants will follow the same schedule for controls and follow-ups as other patients with uveal melanoma. Follow-up examinations are planned 1, 3, 6 and 12 months after primary tumor treatment with either surgery or brachytherapy, followed by annual or semi-annular examinations for life. Radiological examinations, usually with contrast-enhanced ultrasound or computed tomography, are performed every 6 months during the first five years. The population treated with melatonin will later be compared to the control group regarding the primary and secondary outcomes.
There are three reasons why we are not using a placebo in this study:
First, our most important outcomes are determined by the results of the radiological examinations (i.e., whether or not metastases are detected), which leaves little room for the placebo effect. Second, the standard clinical routine for uveal melanoma patients is not to use adjuvant treatments after the primary tumor treatment, but instead monitor patients with regular radiological follow-ups. This routine is followed internationally, with little variation between countries. Third, the risk of metastases and survival in the control group are already well known since it has remained consistent over the past several decades with little variation between different populations and time periods.1,22−35 It is therefore relatively straightforward to compare our control group to previous cohorts that have not received placebo. Therefore, we will be able to confirm that our control group is representative of bigger populations. This comparison would be more difficult if the control group were to receive a placebo.
The primary objective for this trial is to investigate whether adjuvant treatment of non-metastatic uveal melanoma with melatonin 20 mg each night reduces the occurrence of metastasis 5 years after randomization. The outcome will be measured once the last person in the trial has taken their last melatonin tablet. The secondary objectives for the trial are to examine if adjuvant treatment with melatonin 20 mg each night for 5 years after randomization can:
When the last recruited patient has been treated with melatonin for 3 years, interim analyses will be performed. At this point in time, we will compare the occurrence of metastases as well as the overall survival in the melatonin and the control group.
Our hypothesis, based on previous research, is that the group treated with melatonin will have a lower relative risk (RR) for metastasis 5 years after randomization.
Participants will be recruited to the trial from St. Erik Eye Hospital in Stockholm. The national management of uveal melanoma patients is centralized to this institution only. Similarly, the St. Erik Ophthalmic Pathology Laboratory receives most of the eyes with uveal melanoma that have been enucleated throughout the country, meaning that patients will be eligible for the trial regardless of where in Sweden they reside. If the patient is found to meet inclusion and exclusion criteria, they will be contacted via telephone and given information regarding the trial. If the potential participant is interested in taking part in the trial, they will be sent a written consent form and be contacted by a research team member via a service that allows for both video and audio contact, where the potential participant will be able to confirm their identity, ask any questions they may have regarding the trial, and receive additional information. If they wish to participate, they will be asked to sign the consent form (two copies) during the video-call and send one of the signed copies in a prepaid envelope to the research team. Once the signed consent form is received by the research team, the participant will be randomized to either the melatonin or the standard treatment group (control group).
Eligibility criteria
Inclusion criteria:
In addition to meeting these three criteria, at least one of the following criteria (5-11) must be met as well:
Exclusion criteria:
Who will take informed consent?
A research member will obtain informed consent from the trial participants. In Sweden, informed consent must be collected by a licensed physician. The informed consent form will be sent to the participant via post which the participant will sign if they wish to participate in the trial and send it back to the research team who will also sign it and send a copy back to the participant. The participant will then be randomized to either melatonin group or to melatonin group.
The randomization takes place when the participant has sent their signed informed consent form to the research team, agreeing to be a part of this clinical trial. 50 sheets of paper labeled “melatonin” and 50 sheets of paper labeled “control” will be preserved in a total of 100 sealed, identical envelopes, mixed in one box. When the written informed consent is received from a participant, we will randomly choose one of these envelopes and open it. The content will then determine the randomization of the patient i.e., melatonin or control. When the process of randomization is complete, the participant will be informed of the outcome. If they have been randomized to the melatonin group, they will receive a prescription for melatonin and an order will be placed for 15 containers of melatonin tablets (corresponding to 1 year of consumption) each year during the 5-year period. The participating research staff as well as the participants will therefore be aware of their randomization outcome, either to treatment with melatonin or to composing the control group.
Blinding
This trial is not blinded.
Intervention
Participants will be equally randomized into two groups: the melatonin group (treated with 20 mg melatonin each night for five years) or the control group (no intervention). When a patient is recruited and randomized to the melatonin group, blood samples will be ordered by a licensed physician regarding creatinine, electrolytes (Sodium, Potassium) and alanine transaminase (ALAT). This process will be repeated after 2 and 4 years.
Table 1. Study Design.
Time |
Event in clinical routine |
Other events for trial subjects |
At diagnosis |
Clinical examination of the eye. Radiological examination of the thorax and abdomen. Primary treatment*. |
Provide information about the trial. Screen participant for inclusion and exclusion criteria. Obtain written consent. Give medication instructions. Order blood tests to measure kidney function, electrolytes and liver function. Prescribe melatonin 20 mg every night for 5 years. |
1 month |
A |
Ask about AE and SAE, and about prescription compliance. |
6 months |
B |
Ask about AE and SAE, and about prescription compliance. |
1 year |
A+B |
Ask about AE and SAE, and about prescription compliance. |
1.5 years |
B |
Ask about AE and SAE, and about prescription compliance. |
2 years |
A+B |
Ask about AE and SAE, and about prescription compliance. Ordering blood tests to measure kidney function, electrolytes and liver function. |
2.5 years |
B |
Ask about AE and SAE, and about prescription compliance. |
3 years |
A+B |
Ask about AE and SAE, and about prescription compliance. |
3.5 years |
B |
Ask about AE and SAE, and about prescription compliance. |
4 years |
A+B |
Ask about AE and SAE, and about prescription compliance. Order blood tests to measure kidney function, electrolytes and liver function. |
4.5 year |
B |
Ask about AE and SAE, and about prescription compliance. |
5 year |
A+B |
End of melatonin treatment. Evaluation of overall survival, metastasis-free survival, and proportion of subjects with metastases**. Ask about AE and SAE. |
*= Primary treatment of uveal melanoma in the eye is either enucleation (surgical removal of the eye) or brachytherapy (local radiation therapy of the eye).
**=Evaluation of the proportion of subjects with metastases is performed through data collection via registries, chart documentation, and statistical work. It therefore does not require subjects’ active participation.
A= Follow-ups at St. Erik Eye Hospital or at the participants local eye clinic. Examination of the eye, for subjects treated with radiation, or of the prosthesis and/or orbita, for subjects treated with enucleation. Follow-up interval +/- 4 weeks during the first year and +/-8 weeks after the first year.
B = Radiological examination of the liver with ultrasound or computer tomography every six months for the first five years after diagnosis; can be performed at the participant’s local healthcare clinic. Follow-up interval +/- 4 weeks during the first year and +/-8 weeks after the first year.
Table 2. Flow chart
Time |
Screening
- 30 days before 1 m visit |
Month 1
+/-7 days |
Month 6
+/- 4 weeks |
Year 1
+/- 4 weeks |
Year 1,5
+/- 8 weeks |
Year 2
+/- 8 weeks |
Year 2,5
+/- 8 weeks |
Year 3
+/- 8 weeks |
Year 3,5
+/- 8 weeks |
Year 4
+/- 8 weeks |
Year 4,5
+/- 8 weeks |
Year 5
+/- 8 weeks |
Inclusion/ |
x |
|
|
|
|
|
|
|
|
|
|
|
Informed consent |
x |
|
|
|
|
|
|
|
|
|
|
|
Randomization melatonin/ |
x |
|
|
|
|
|
|
|
|
|
|
|
Medical history, current medication |
x |
|
|
|
|
|
|
|
|
|
|
|
Medication instruction |
x |
|
|
|
|
|
|
|
|
|
|
|
Radiological examination – liver |
|
|
x |
x |
x |
x |
x |
x |
x |
x |
x |
x |
Radiological examination – thorax and abdomen |
x |
|
|
|
|
|
|
|
|
|
|
|
Blood samples |
x |
|
|
|
|
x |
|
|
|
x |
|
|
AE & SAE, prescription compliance |
|
x |
x
|
x |
x |
x |
x |
x |
x |
x |
x |
x |
End of study |
|
|
|
|
|
|
|
|
|
|
|
x |
Data collection
A case report form (CRF) will be established in paper form and used for data collection, where subjects will be identified through a trial-specific number only. The examiner is responsible for assuring that registered information is correct and complete, and that the reporting is performed according to the predetermined timeline. The principal investigator will sign the completed CRF and a copy will be archived where the trial takes place.
The subjects will take their medication (tablets) at home and confirm that they have received each package of melatonin sent to them. They will, one month following recruitment, be contacted via telephone and asked about their compliance to the treatment. The participants will then continue to be contacted via telephone every six months throughout the trial period and asked questions about compliance, adverse events (AE) and serious adverse events (SAE). After the termination of the trial, the subjects will continue their yearly control visits at St. Erik Eye Hospital, or at their local ophthalmology clinic, for the remainder of their lives, as all uveal melanoma patients do.
In the event of detection of metastases
If a suspected metastasis is detected in radiological examinations and then verified with a biopsy, the patient will be referred by their physician to an oncology clinic in their home region. This is a standard clinical routine and will not be impacted by this trial. The oncology clinic will make a decision regarding next steps to investigate, examine and treat the metastases. Patients with metastases typically receive systemic chemotherapy, immunotherapy with so-called checkpoint inhibitors, and/or regional perfusion treatment of the liver where high doses of chemotherapy are injected into the liver's circulatory system. These treatments are demanding for patients and can result in side effects such as fatigue, susceptibility to infection, dry mucous membranes, and pain. The average survival following metastasis detection is about one year. Metastasis detection does not alter the melatonin doses or treatment instructions in this trial. Melatonin given at a dose of 20 mg at 10 pm has shown particularly positive effects in advanced stages of cancer in earlier studies.10
It has also been reported that systemic chemotherapy is more easily tolerated in patients who are simultaneously treated with melatonin, particularly in regards to neurotoxicity, thrombocytopenia, weight loss, and asthenia.44 Furthermore, there are fewer cases of alopecia (hair loss) and infection in patients taking 20 mg of melatonin at 10 pm while undergoing radiotherapy.45 If participants in this trial take melatonin from the time that their metastases are detected, the metastases will be included in both the intention-to-treat as well as the per protocol analysis. Survival in the melatonin group following metastasis detection will therefore be counted in the patients still taking melatonin.
Subjects may voluntarily withdraw from the trial at any time without impacting further standard treatment. The principal investigator reserves the final right to terminate the trial for a specific subject due to unacceptable side effects or poor compliance. If a subject terminates their participation in this trial, their trial-specific ID will not be re-used. They will not be able to re-join the trial. No further data will be collected, however, data that has already been collected will be used for the final analysis of the trial. Participants who withdraw within 6 months following randomization will be replaced by newly recruited and randomized patients with a ratio of 1:1 i.e., if two participants withdraw from the trial within 6 months, they will be replaced by two new participants. Patients who withdraw from the trial after 6 months following randomization will not be replaced.
Our power calculations will be based on the following:
A previously calculated metastasis incidence of 60% five years following diagnosis for individuals not taking melatonin (participants in the control group). This is a relevant calculation considering the high-risk population recruited based on our inclusion criteria.46–49
An earlier study which included study participants with surgically removed lymph node metastases of malignant melanoma which showed that 31% (5 of 16 participants) of those treated with 20 mg of evening melatonin developed distant metastases compared to 71% (10 of 14 participants) of those not treated with melatonin.8
Based on this previous research, the following assumptions are made:
The number of participants in the melatonin group which will have developed distant metastases after 5 years: 30%
The number of participants in the control group which will have developed distant metastases after 5 years: 60%.
Alpha: 0,05
Beta: 0,2
Power: 80%
Results: 42 participants must be included in each group, i.e., both the melatonin and the control group, in order to achieve statistical significance (Table 3). To obtain a safety margin in case some participants withdraw from the trial, we will strive after a group population of 50 participants per group.
Melatonin, n= | 42 |
---|---|
Control, n= | 42 |
Incidence, melatonin group | 30% |
Incidence, control group | 60% |
Alpha | 0,05 |
Beta | 0,2 |
Power | 0.8 |
The primary outcome is the number of patients which develop metastasis in the melatonin group vs. the control group. This will be evaluated as a relative risk (RR), measured as relative risk with a 95% confidence interval. The secondary outcomes include the following:
Number of patients developing metastasis in the melatonin group vs. the control group in 5 years, evaluated as Cox regression hazard ratio (HR), measured as hazard ratio with relevant covariants, with a 95% confidence interval.
The overall 5-year survival from randomization in the melatonin group vs. control group, evaluated with the Log-Rank test through Kaplan-Meier curve.
The overall 5-year survival from the detection of metastasis in the melatonin group vs. control group, evaluated with the Log-Rank test through Kaplan-Meier curve.
Number of patients which develop other types of cancer in the melatonin group vs. control group, evaluated as relative risk (RR), measured as relative risk with 95% confidence interval.
Number of patients developing other cancers in the melatonin group vs. control group, evaluated as Cox regression hazard ratio (HR), measured as hazard ration with relevant covariants, with 95% confidence interval.
Number of patients with AE and SAE in the melatonin group vs. control group, assessed by CTCAE and evaluated as relative risk (RR) with a 95% confidence interval.
Other outcome measures:
Interim analysis: number of patients developing metastasis within 3 years in the melatonin group vs. control group, evaluated as relative risk (RR), measured as relative risk with 95% confidence interval.
Interim analysis: overall survival in 3 years in the melatonin group vs. control group, evaluated with the Log-rank test.
Our primary and secondary outcomes for the clinical effects of melatonin treatment will be performed through data collected from patient charts, where it is registered if the subject has developed metastasis, if they are deceased, and/or if they have received another cancer diagnosis in addition to uveal melanoma.
Our outcomes for clinical safety will be the number of adverse events (AE), the number of serious adverse events (SAE), and the number of suspected unexpected serious adverse reactions (SUSAR) in the melatonin group and control group respectively. These will be measured through data collected from CRF forms and patients’ chart documentations. The subjects are encouraged to contact us is they experience side effects, or new or worsened symptoms. They will be asked about AE and SAE at three months and 1 year after starting melatonin treatment, and thereafter every six months until 5 years have passed since recruitment.
The trial will be terminated when the last participant in this trial has had their five-year control (Last Subject Last Visit - LSLV). No further treatment or contact with the participants will be made after this point of time.
We will be analyzing our data according to “intention to treat” where all participants randomized to either the melatonin or control group are included in said group regardless even if some terminate their participation in the trial or are excluded from the trial later on. We will at the same time analyze our data “per protocol” where the participants who terminate their participation during the trial or are noncompliant to melatonin treatment are excluded from analysis.
To answer our primary and secondary objectives, we will use both the Chi-square test and the Log-rank test of cumulative survival with associated 95% confidence intervals and p-values. Relative risk will be calculated as the probability of metastasis in the melatonin group divided by the risk of metastasis in the control group.
P values less than 0.05 will be considered significant, and all tests will be double-tailed, or two-sided.
The Shapiro-Wilk test will be used to confirm if our continuous data is normally distributed.
A Student’s t-test will be used to compare the differences in normally distributed continuous data within the melatonin and control group, respectively. Data found not to be normally distributed data will be compared using the Mann Whitney U-test.
In order to compare the risk of death and metastasis between the melatonin and control group, we will use a Cox Regression, adjusted for covariates such as tumor size, T category, cell type, presence of extra scleral growth, presence of extracellular matrix patterns and BAP-1 expression.
Interim analysis will take place after two and three years during the trial.
In order to assure that the trial is performed according to the protocol - that the data is collected, documented and reported according to ICH-GCP as well as regarding ethical and regulatory requirements - the trial will be monitored by an independent monitor before the start of the trial, during the course of the trial, and after the trial ends, through Karolinska Trial Alliance. This will take place according to the monitoring plan for the trial and aims to ensure the rights, safety and well-being of participants as well as to oversee that data in the CRF forms is filled in correctly.
An AE is defined as any unfavorable event or worsening of an existing medical state in a subject that receives a trial medication, regardless of causation. An SAE is a serious event where a specific dose leads to death, is life threatening, requires health care, causes remaining or massive invalidation or disability, or causes an abnormality or malformation. A SUSAR is defined as a side effect or an incident that is serious, unexpected, and suspected to be caused by the treatment. Subjects will be encouraged to contact the principal investigator if any of these incidents occur. They will also be specifically asked about AE, SAE, and SUSAR after one month of treatment and at regular follow-ups throughout the course of the trial. All AE will be registered in the CRF and evaluated in regards to causation, intensity and if the incident is classified as an AE or an SAE. SAE will be reported in a specific form and submitted to the principal investigator within a day. SUSAR will be evaluated by a licensed physician and further reported to The Swedish Medical Products Agency and the physicians that have met the subject during check-ups. Lethal or life threatening SUSAR will be reported within a week and complemented with other relevant information within the 8 days following, while other types of SUSAR will be reported within 15 days.
The principal investigator will evaluate possible causation between AE/SAE and melatonin usage. If such an association is found, the subjects will be followed until declared healthy, until a “near healthy” status is declared, or until the principal investigator considers no further need for follow-up. All AE/SAE will be categorized as probably related, possibly related or not related. Probably related events are defined as clinical events, including abnormal laboratory analysis results occurring at a reasonable time following melatonin administration, if the event is unlikely to be related to an underlying disease or another medication, or if the symptoms are previously known side effects of melatonin. Possibly related events are defined as clinical events, including abnormal laboratory analysis results occurring after a reasonable time following melatonin treatment, where the event can be explained by the usage of melatonin, but there is not sufficient information to ensure the causation exists. Not related events are defined as clinical events including abnormal laboratory analysis results occurring at an unreasonable time as related to melatonin treatment, thereby suggesting the event likely not related to the intervention (melatonin) and can be explained by another medication or underlying disease.
Unfavorable medical events will be classified and graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. based on the following:
Grade 1: | Mild Asymptomatic or mild symptoms Only clinical or diagnostic observations; intervention not indicated |
---|---|
Grade 2: | Moderate Minimal, local, or non-invasive interventions indicated; affects age-adjusted ADL |
Grade 3: | Severe Medically significant but not acutely life threatening; hospitalization or lengthened health care indicated; disabling; limits personal ADL |
Grade 4: | Life threatening Life threatening consequences, acute interventions indicated |
Grade 5: | Death related to side effects. |
In urgent situations, the principal investigator will immediately take urgent safety measurements required to protect the subjects, such as temporarily terminating the clinical trial medication or implementing additional monitoring measures. An overdose of medication associated with AE will be registered as a diagnosis or symptom in the CRF, and in the subject’s journal documentation if no associated symptoms are found. Women of fertile age will be excluded from this trial.
All study participants will be insured via LÖF (Landstingens regionernas ömsesidiga försäkringsbolag.
This study protocol follows the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines.50 In order to communicate the trial results to participants, healthcare professionals and the public we plan to publish our findings in peer-reviewed journals and present them at both domestic and international scientific conferences.
Melatonin is a hormone which positively impacts our immune system, inhibits angiogenesis, and stimulates apoptosis in malignant cells. This hormone may be a suitable candidate for an adjuvant treatment in uveal melanoma, particularly for patients with high risk for metastasis development but do not yet have detectable metastases at diagnosis.14
A dose of 20 mg per day or higher has been used in at least 14 earlier randomized clinical studies for patients that have been diagnosed with various forms of cancer.8–10,13,44,49,51−53 16–18, 21,30, 45–52, 54 In eight of these studies, the treatment has been used for at least a year in a total of 651 patients (30 + 356 + 49 + 14 + 12 + 55 + 35 + 100) in the melatonin group.8–10,13,44,49,51−53 In these clinical trials when the median patient had been treated with 20 mg melatonin per day for a year or longer, no blood samples or other tests were taken regarding subclinical AE, i.e. leucopenia, thrombocytopenia, hyperglycemia, hypokalemia, hyponatremia, hyperbilirubinemia, and proteinuria.8–10, 13,44,51 One exception is the clinical trial performed by Lissoni et al. where 100 patients with metastasized lung cancer were randomized to either systemic chemotherapy or systemic chemotherapy with melatonin. In this study, thrombocytopenia was evaluated, which was significantly lower in the melatonin group.44 In another study, blood samples were taken to measure white blood cells and eosinophils during each cycle of IL-2 in patients with advanced gastrointestinal cancer treated with 50 mg of melatonin at 10 pm during one week per month as an adjuvant treatment.52
Regarding toxicity and adverse events, these studies have in general reported few side effects of melatonin, such as mild anxiety, though subjects in another study experience decreased anxiety.8,51 In most studies, no differences in side effect outcomes between melatonin and placebo groups were found regarding melatonin-related toxicity including nausea or other gastrointestinal issues.8 One study found no significant differences in Quality OF Life (QOL) QLQ-C30 or in side effect subcategories including physical, emotional, cognitive, social, fatigue, nausea, pain, insomnia, lack of appetite, obstipation or diarrea.9 No cardiovascular, pulmonal, renal, or hematological complications were observed when using melatonin as an adjuvant treatment to IL-2 in patients with advanced gastrointestinal cancer.52 To the contrary, some studies reported a better cytotoxic chemotherapy response regarding neurotoxicity, thrombocytopenia and asthenia in groups receiving melatonin as well as significantly fewer complications involving infections related to radiation therapy and/or steroid treatments.44,51 Other studies found an improvement in the Karnofsky Performance Scale in the melatonin group.52,53
The toxicity of melatonin has been low in earlier animal and human studies. In animals, an LD50 (lethal dose in 50% of experimental animals) could not be established since no doses, to date, have been proven to be lethal. The highest used daily dose known for the sponsor is 800 mg/kg body weight in mice (corresponding to 60 g for a 75 kg body weight). A higher dose could not be attained since higher doses were not water soluble.54 In one study, 5 patients with hyperpigmented skin who received 1 g melatonin /day for 25–30 days were observed to have slightly lower levels of growth hormone, luteinizing hormone, follicle stimulating hormone and cortisol during treatment. However, there were no changes in their hematological status (white blood cells, hemoglobin, hematocrit, thrombocytes, reticulocytes and differential white blood cells count), plasma creatinine, uric acid, calcium, phosphate, transaminases, LDH, bilirubin, total protein, albumin, thyroxin or of retinal appearance.55 In a study performed on 11 patients with Parkinson’s disease that received 50–100 mg melatonin daily, no changes in serotonin levels in urine was observed. At least one other previous study has had participants take 20 mg of melatonin every evening for five years.56 In this study, patients with metastasized non-small cell lung cancer were randomized to treatment with either cisplatin and etoposide or to cisplatin, etoposide and melatonin. The patients who received melatonin were found to have both significantly better overall survival and significantly fewer reported side effects.56
Animal studies indicate that melatonin can downregulate the pituitary-gonadal axis, which may result in hypogonadism or delayed puberty.55,57 Treatment with low doses (2 mg) of melatonin in men did not, however, change blood levels of testosterone or luteinizing hormone.58 Treatment with melatonin in women has been shown to lower the secretion of gonadotropin in a rapport from a clinical phase II-study where 1400 women were treated with 75 mg melatonin each evening for four years, though no other side effects were observed.59 Considering these findings, prepubescent children and women of reproductive age will be excluded from this trial.
Even if melatonin has shown potential as an adjuvant treatment of cancer including uveal melanoma, the timing of melatonin consumption is relevant as it is a hormone which is naturally secreted at 10 pm in the absence of light.60 Melatonin given at the wrong time point in the circadian rhythm might have the opposite effect.14 Melatonin injections given in the morning have been shown to stimulate the growth of fibrosarcoma and Erlich tumors, while injections at 10 pm inhibit tumor growth.61 Furthermore, melatonin distribution several at multiple occasions during both day and night was found to exacerbate depressive symptoms.62 In a study performed on rats, treatment with peritoneal injections of 100 µg melatonin/day (corresponding to 30 mg/day given to an adult) were found to have more photoreceptor damage in the retina after illumination with high intensity fluorescence light of 1600 lux for 24 hours, compared to animals treated with placebo.63 Therefore, as melatonin is a hormone important to our natural circadian rhythm, it is important to consider the timing of melatonin consumption, ideally at 10 pm.
If melatonin is found to prevent the development of metastases, there would be benefits for both the trial participants who took melatonin during the trial and for patients diagnosed with uveal melanoma in the future. By sharing our results in research articles or by other means, this benefit could become available to patients beyond Sweden’s borders as well. Melatonin is relatively accessible worldwide and could potentially reduce mortality for a large proportion of the 7000 patients diagnosed with the disease annually around the globe. We therefore believe that the benefits of this trial outweigh the limited potential risks.
Since data regarding the effects of melatonin as an adjuvant treatment in uveal melanoma is limited, this future clinical trial will be performed to investigate if adjuvant treatment with melatonin following diagnosis of the primary tumor, decreases the risk of developing macrometastases of uveal melanoma.
The recruitment of patients for this trial will begin on September 23, 2022. The authors expect to complete this procedure by September 2026. Our trial protocol has been approved and registered by the Swedish Medical Products Agency on June 22, 2022 (EU No. 2022-500307-49-00). Our trial registration number is NCT05502900.
Crucial changes in the signed protocol will be registered in protocol amendment and further submitted through CTIS for approval.
AE: Adverse event
CRF: Case report form
CTIS: Clinical trial information system
CTR: Clinical trial regulation
GCP: Good clinical practice
ICH: International Council for Harmonization
ITT: Intention-to-treat
PP: Per protocol analysis
SAE: Serious adverse event /Serious adverse reaction
SUSAR: Suspected unexpected serious adverse reaction
Acknowledgements
We would like to acknowledge Heléne Sjöö, a clinical trial official and educator at Karolinska Trial Alliance, for her guidance and support in formatting our study protocol and case report form.
Authors’ contributions
GS is the principal investigator; he conceived the study, drafted the proposal and led the development of the study protocol. RKO and AH are members of the research team and contributed to the development of the case report form and study protocol. All authors have read and approved the final manuscript.
Funding
The authors of this paper have received funding from the following sources:
St. Erik Eye Hospital
The Swedish Society of Medicine (SLS-971390)
The Royal Swedish Academy of Sciences (ME2019-0036)
The Swedish Cancer Society (20 0798 Fk)
Region Stockholm (RS-2019-1138)
The Swedish Eye Foundation (2022-05-02)
Karolinska Institutet (FS-2021-0010)
Availability of data and material
All investigators as well as the monitoring organization will have access to the final trial dataset. There are no contractual agreements that limit such access for investigators. The collection of personal information including but not limited to names, addresses, social security numbers, and other contact details about the trial's participants, and disclosure of such information to any party, is regulated by the The Swedish Medical Products Agency and subject to approval from the Swedish Ethical Review Authority.
Ethics approval and consent to participate
The trial is going to be performed according to the trial protocol, CTR regarding human medicine (536/2014), Helsinki declaration, ICH-GCP, and the current national regulation relevant to this clinical trial. EU-trial number: 2022-500307-49-00. The trial is approved by The Swedish Medical Products Agency and The Swedish Ethical Review Authority.
Signed informed consent forms will be obtained from all trial participants (see methods section for more information).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.